help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism Vol. 59, No. 4 705-709
doi:10.1210/jcem-59-4-705
Copyright © 1984 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SASSOLAS, G.
Right arrow Articles by UNDERWOOD, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SASSOLAS, G.
Right arrow Articles by UNDERWOOD, L.

Effects of Human Pancreatic Tumor Growth Hormone-Releasing Hormone (hpGRHl-44-NH2) on Immunoreactive and Bioactive Plasma Growth Hormone in Normal Young Men*

GENEVIEVE SASSOLAS, PIERRE CHATELAIN, RICHARD COHEN, JEAN PIERRE BOISSEL, SYLVIANE LAPORTE, JACQUES GALLEYRAND, BRUNO CLAUSTRAT, ABDEL ELMCHARFI, JEAN-ALAIN CHAYVIALLE, HELENE COHEN, SERGE FERRY and LOUIS UNDERWOOD

Centre de Medecine Nucleaire, Unite de Soins Hospital Neuro-Cardiologique, 69003 Lyon, France
Service de Radioanalyse Hospital Neuro-Cardiologique, 69003 Lyon, France
Department de Pharmacologie Clinique Hospital Neuro-Cardiologique, 69003 Lyon, France
Service Pharmaceutique Hospital Neuro-Cardiologique, 69003 Lyon, France
Inserm U34 Hopital Debrousse, 69005 Lyon, France
Inserm U45 Hopital Edouard Herriot, 69374 Lyon, France
Department of Pediatrics University of North Carolina, Chapel Hill, North Carolina 27514

Address requests for reprints to: Genevieve Sassolas, Centre de Medecine Nucleaire, Hopital Neuro-Cardiologique, 59 Boulevard Pinel, 69394 Lyon Cedex 3, France.

Synthetic human pancreatic tumor GH-releasing hormone (hpGRH l-44-NH2) was given by iv bolus injection to 10 normal men at doses of 75, 150, 300, and 600 µg. At all doses the plasma GH responses were similar in an individual subject. Among subjects, however, the responses were significantly different, with peak GH concentrations ranging between 9.0 µg/liter and 54.9 µg/liter. The GH released in response to GRH was bioactive in the Nb2 lymphoma cell multiplication assay. The circulating GH 30 and 60 min after GRH was detected in 3 molecular forms corresponding to little, big, and big-big GH. These forms averaged 50%, 30%, and 20% of the total immunoreactive GH, respectively. The mean rise of plasma somatomedin-C, from 1.86 U/ml to 2.21 U/ml 24 h after GRH, was not statistically significant. A small but statistically significant GRH dose-dependent rise in plasma PRL (mean PRL concentrations 10 min after 600 fig GRH, 11.13 µg/liter occurred consistently after GRH injection. The evidence that the GH released by GRH is bioactive supports the potential use of GRH for therapeutic applications.

* This work was supported by Fondation pour la Recherche Medicale Francaise, by SANOFI, and by USPHS Grant AM-01022.

Received December 13, 1983.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society